News

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy
Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...
FDA appoints biotech veteran George Tidmarsh to lead drug evaluation division
Stanford's George Tidmarsh has authored 143 scientific papers and patents, as well as played a central role in developing ...
Biotech exec George Tidmarsh picked as FDA's chief drug regulator
The U.S. Food and Drug Administration named ex-biotech exec George Tidmarsh as its chief drug regulator. FDA Commissioner ...
FDA appoints biotech executive as top drug regulator under RFK Jr.
Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...
Former biotech executive appointed to lead FDA drug review office
George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...
FDA names former pharmaceutical company executive to oversee US drug program
The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.
The FDA recalled Power Stick deodorant. Here is what to know
Pennsylvania-based A.P. Deauville, LLC is recalling several types of its Power Stick deodorant, due to a process issue.
FDA recalls Power Stick; what to know about deodorant recall 2025
Pennsylvania-based A.P. Deauville, LLC is recalling several types of its Power Stick deodorant, due to a process issue.
FDA Issues Risk Warning for Bread Recall Update
The FDA's assessment of the bread recall has designated it as a Class II risk, which means the product "may cause temporary ...
STAT18h
New head of FDA drug center is a biotech veteran and an outspoken critic of the academic establishment
“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development — ...
Replimune Shares Plumb All-Time Lows After FDA Rejection
Replimune shares collapsed on Tuesday after the U.S. Food and Drug Administration rejected the clinical-stage biotechnology company's proposed advanced melanoma treatment. Shares of the Woburn, Mass., ...